Loading…
Mid-Link Testing Company, Ltd, a medical device testing facility in China, was cited for objectionable conditions related to Good Laboratory Practice (GLP) nonclinical studies conducted between February 26 and March 6, 2024. The FDA's Office of Bioresearch Monitoring Operations identified violations in acute systemic toxicity tests, rabbit pyrogen tests, MTT cytotoxicity assays, and guinea pig maximization tests (GPMT) that support investigational device exemptions and premarket approval applications. These compliance failures raised concerns about the scientific validity of data submitted to the FDA for medical device development. The company was required to provide prompt corrective actions in response to the violations documented during the inspection.